Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors

Photochemistry and Photobiology

Volumn 73, Issue 4, 2001, Pages 403-409

  Korbelik, Mladen ^a,c   Sun, Jinghai ^a   Posakony, Jeffrey J ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTYLCHLORIN E6; BCG VACCINE; BENZOPORPHYRIN DERIVATIVE; CGP 55847; LUTETIUM TEXAPHYRIN; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ZINC; TEMOPORFIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; LYMPH NODE; MEMORY CELL; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; SUBCUTANEOUS TISSUE TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BCG VACCINE; COMBINED MODALITY THERAPY; DIHEMATOPORPHYRIN ETHER; DRUG COMBINATIONS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

ANIMALIA; MYCOBACTERIUM BOVIS BCG;

EID: 0035324352     PISSN: 00318655     EISSN: None     Source Type: Journal    
DOI: 10.1562/0031-8655(2001)073<0403:IBPTAB>2.0.CO;2     Document Type: Article

References (51)

1. Dougherty, T. J., C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan and Q. Peng (1998) Photodynamic therapy. J. Natl. Cancer Inst. 90, 889-905.
2. Henderson, B. W. and T. J. Dougherty (1992) How does photodynamic therapy work? Photochem. Photobiol. 55, 145-157.
3. Korbelik, M. (1996) Induction of tumor immunity by photodynamic therapy. J. Clin. Laser Med. Surg. 14, 329-334.
4. Gomer, C. J., M. Luna, A. Ferrario, S. Wong, A. M. R. Fisher and N. Rucker (1996) Cellular targets and molecular responses associated with photodynamic therapy. J. Clin. Laser Med. Surg. 14, 315-321.
5. Korbelik, M. (1999) Antitumor immune reaction elicited by photodynamic therapy. Proc. SPIE 3601, 82-88.
6. Fingar, V. H. (1996) Vascular effects of photodynamic therapy. J. Clin. Laser Med. Surg. 14, 323-328.
7. Krosl, G., M. Korbelik and G. J. Dougherty (1995) Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy, Br. J. Cancer 71, 549-555.
8. Gollnick, S. O., X. Liu, B. Owczarczak, D. A. Musser and B, W. Henderson (1997) Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res. 57, 3904-3909.
9. Korbelik, M. and I. Cecic (1999) Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 37, 91-98.
10. de Vree, W. J. A., M. C. Essers, H. S. de Bruijn, W. M. Star, J. F. Koster and W. Sluiter (1996) Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res. 56, 2908-2911.
11. Korbelik, M., G. Krosl, J. Krosl and G. J. Dougherty (1996) The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res. 56, 5647-5652.
12. Korbelik, M. and G. J. Dougherty (1999) Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 59, 1941-1946.
13. Korbelik, M. and J. Sun (1998) Cancer treatment by photodynamic therapy combined with NK cell line based adoptive immunotherapy. Proc. SPIE 3254, 4-11.
14. Korbelik, M., J. Sun, V. R. Naraparaju and N. Yamamoto (1999) Eradication of solid cancers by photodynamic therapy combined with dendritic cell-based adoptive immunotherapy. Cancer Res. Proc. 40, 86.
15. Cho, Y. H., R. C. Straight and J. C. Smith (1992) Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model. J. Urol. 147, 743-746.
16. Korbelik, M. and I. Cecic (1998) Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. J. Photochem. Photobiol. B: Biol. 44, 151-158.
17. Myers, R. C., B. H. S. Lau, D. Y. Kunihira, R. R. Torrey, J. L. Wooley and J. Tosk (1989) Modulation of hematoporphyrin derivative-sensitized phototherapy with Corynebacterium parvum in murine transitional cell carcinoma. Urology 33, 230-235.
18. Herr, H. W., D. M. Schwalb, Z. F. Zhang, P. C. Sogani, W. R. Fair, W. F. Whitmore Jr. and H. F. Oettgen (1995) Intravesical Bacillus Calmette-Guérin therapy prevents tumor progression and deaths from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. Clin. Oncol. 13, 1404-1408.
19. Schuitmaker, J. J., P. Baas, H. L. L. M. van Leengoed, F. W. van der Meulen, W. M. Star and N. van Zandwijk (1996) Photodynamic therapy: a promising new modality for the treatment of cancer. J. Photochem. Photobiol. B: Biol. 34, 3-12.
20. Nseyo, U., J. Dehaven and T. J. Dougherty (1998) Photodynamic therapy (PDT) in the management of patients with resistant superficial bladder cancer: a long term experience. J. Clin. Laser Med. Surg. 16, 61-68.
21. Ratliff, T. L., D. Gillen and W. J. Catalona (1997) Requirement of a thymus-dependent immune response for BCG-mediated antitumor activity. J. Urol. 137, 155-158.
22. Böhle, A., C. Nowc, A. J. Ulmer, J. Musehold, J. Gerdes, A. G. Hofstetter and H.-D. Flad (1990) Detection of urinary TNF, IL-1, and IL-2 after local BCG immunotherapy for bladder carcinoma. Cytokine 2, 175-181.
23. de Reijke, T. M., E. C. de Boer, K. H. Kurth and D. H. Schamhart (1996) Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol. 155, 477-482.
24. Taniguchi, K., S. Koga, M. Nishikido, S. Yamashita, T. Sakuragi, H. Kanetake and Y. Saito (1999) Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer. Clin. Exp. Immunol. 115, 131-135.
25. Prescott, S., K. James, T. B. Hargreave, G. D. Chisholm and J. F. Smyth (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol. 147, 1636-1642.
26. Conti, P., M. Reale, M. Nicolai, R. C. Barbacane, F. C. Placido, R. Iantorno and R. Tenaglia (1994) Bacillus Calmette-Guérin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients. Cancer Immunol. Immunother. 38, 365-371.
27. Kim, D., H. G. Lee, J. K. Kim, S. N. Park, I. S. Choe, Y. K. Choe, S. J. Kim, E. Lee and J. S. Lim (1999) Enhanced antigenpresenting activity and tumor necrosis factor-alpha-independent activation of dendritic cells following treatment with Mycobacterium bovis bacillus Calmette-Guérin. Immunology 97, 626-633.
28. Ratliff, T. L. (1992) Role of the immune response in BCG for bladder cancer. Eur. Urol. 21(Suppl. 2), 17-21.
29. Patard, J. J., D. K. Chopin and L. Boccon-Gibod (1993) Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. World J. Urol. 11, 165-168.
30. Böhle, A., A. Thanhäuser, A. J. Ukmer, T. Mattern, M. Ernst, H.-D. Flad and D. Jocham (1994) On the mode of action of intravesical bacillus Calmette-Guérin: in vitro characterization of BCG-activated killer cells. Urol. Res. 22, 185-190.
31. Korbelik, M. and G. Krosl (1996) Photofrin accumulation in malignant and host cell populations of various tumours. Br. J. Cancer 73, 506-513.
32. Krosl, G. and M. Korbelik (1994) Potentiation of photodynamic therapy by immunotherapy: the effect of schizophyllan (SPG). Cancer Lett, 84, 43-49.
33. 3-binding protein has a potent adjuvant activity for immunization. Immunol. Cell. Biol. 76, 237-244.
34. Baldwin, R. W. and M. V. Pimm (1973) BCG immunotherapy of rat tumors of defined immunogenicity. Natl. Cancer Inst. Monogr. 39, 11-19.
35. Baldwin, R. W., D. G. Hopper and M. V. Pimm (1976) Bacillus Calmette-Guéin contact immunotherapy of local and metastatic deposits of rat tumors. Ann. N.Y. Acad. Sci. 277, 124-134.
36. Milanesi, C., C. Zhou, R. Biolo and G. Jori (1990) Zn(II)-phthalocyanine as a photodynamic agent for tumours. II. Studies on the mechanism of photosensitized tumour necrosis. Br. J. Cancer 61, 846-850.
37. Carlos, T. M. and J. M. Harlan (1994) Leukocyte-endothelial adhesion molecules. Blood 84, 2068-2101.
38. Trottein, F., S. Nutten, J.-P. Papin, C. Leportier, O. Poulain-Godefroy, A. Capron and M. Capron (1997) Role of adhesion molecules of the selectin-carbohydrate families in antibody-dependent cell-mediated cytotoxicity to schistosome targets. J. Immunol. 159, 804-811.
39. Putz, E. F. and D. N. Mannel (1996) A role for L-selectin in monocyte activation by Jurkat tumour cells. Scand. J. Immunol. 44, 556-564.
40. Winters, W. D. and D. L. Lamm (1981) Antibody responses to bacillus Calmette-Guérin during immunotherapy in bladder cancer patients. Cancer Res. 41, 2672-2676.
41. Sprent, J. (1994) T and B memory cells. Cell 76, 315-322.
42. Gollnick, S. O., D. A. Musser and B. W. Henderson (1998) Photodynamic therapy affects the expression of IL-6 and IL-10 in vivo. Conference on Laser-Tissue Interaction IX, International Biomedical Optics Symposium BiOS'98, San Jose, CA, 24-30 January 1998.
43. Kelley, D. R., T. L. Ratliff, W. J. Catalona, A. Shapiro, J. M. Lage, W. C. Bauer, E. O. Haaf and S. M. Dresner (1985) Intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: effects of bacillus Calmette-Guérin viability on treatment results. J. Urol. 134, 48-53.
44. Woodburn, K. W., Q. Fan, D. R. Miles, D. Kessel, Y. Luo and S. W. Young (1997) Localization and efficacy analysis of the phototherapeutic Lutetium Texaphyrin (PCI-0123) in the murine EMT6 sarcoma model. Photochem. Photobiol. 65, 410-415.
45. Schieweck, K., H.-G. Capraro, U. Isele, P. van Hoogevest, M. Ochsner, T. Maurer and E. Batt (1994) CGP 55847, liposome-delivered zinc (II)-phthalocyanine as a phototherapeutic agent for tumors. Proc. SPIE 2078, 107-118.
46. McMahon, K. S., T. J. Wieman, P. H. Moore and V. H. Fingar (1994) Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage and tumor response. Cancer Res. 54, 5374-5379.
47. Schmidt-Erfurth, U., W. Bauman, E. Gragoudas, T. J. Flotte, N. A. Michaud, R. Birngruber and T. Hasan (1994) Photodynamic therapy of experimental choroidal melanoma using lipoprotein-derived benzoporphyrin. Ophthamology 101, 89-99.
48. Young, S. W., K. W. Woodburn, M. Wright, T. D. Mody, Q. Fan, J. L. Sessler, W. C. Dow and R. A. Miller (1996) Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem. Photobiol. 63, 892-897.
49. van Geel, I. P. J., H. Oppelaar, Y. G. Oussoren, J. J. Schuitmaker and F. A. Stewart (1995) Mechansims for optimizing photodynamic therapy: second-generation photosensitizers in combination with mitomycin C. Br. J. Cancer 72, 344-350.
50. Günther, J. H., A. Jurczok, T. Wulf, S. Brandau, I. Deinert, D. Jocham and A. Böhle (1999) Optimizing syngeneic orthotopic murine bladder cancer. Cancer Res. 59, 2834-2837.
51. Lamm, D. L., A. D. van der Meijden and A. Morales (1992) Incidence and treatment of complications of Bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J. Urol. 147, 596-600.